|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 11/10/15 Revance Therapeutics, Inc. 10-Q 9/30/15 66:5.6M |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 644K
2: EX-10.1 Material Contract HTML 28K
3: EX-10.2 Material Contract HTML 68K
4: EX-10.3 Material Contract HTML 64K
5: EX-10.4 Material Contract HTML 70K
6: EX-10.5 Material Contract HTML 68K
7: EX-10.6 Material Contract HTML 70K
8: EX-31.1 Certification -- §302 - SOA'02 HTML 27K
9: EX-31.2 Certification -- §302 - SOA'02 HTML 27K
10: EX-32.1 Certification -- §906 - SOA'02 HTML 23K
11: EX-32.2 Certification -- §906 - SOA'02 HTML 23K
45: R1 Document and Entity Information HTML 39K
35: R2 Condensed Consolidated Balance Sheets HTML 99K
43: R3 Condensed Consolidated Balance Sheets HTML 31K
(Parenthetical)
48: R4 Condensed Consolidated Statement of Operations and HTML 92K
Comprehensive Loss
61: R5 Consolidated Statements of Cash Flows HTML 171K
37: R6 The Company and Basis of Presentation HTML 36K
42: R7 Summary of Significant Accounting Policies HTML 39K
32: R8 Medicis Settlement HTML 30K
25: R9 Cash Equivalents and Investments HTML 82K
62: R10 Fair Value Measurements HTML 82K
50: R11 Notes Payable and Financing Obligation HTML 41K
49: R12 Convertible Notes, Warrants, and Related HTML 26K
Derivatives
54: R13 Interest Expense HTML 62K
55: R14 Commitments and Contingencies HTML 40K
53: R15 Warrants HTML 22K
56: R16 Equity HTML 105K
44: R17 Net Loss per Share Attributable to Common HTML 62K
Stockholders
46: R18 Subsequent Events HTML 25K
52: R19 Summary of Significant Accounting Policies HTML 52K
(Policies)
66: R20 Cash Equivalents and Investments (Tables) HTML 78K
58: R21 Fair Value Measurements (Tables) HTML 79K
39: R22 Notes Payable and Financing Obligation (Tables) HTML 27K
51: R23 Interest Expense (Tables) HTML 60K
41: R24 Commitments and Contingencies (Tables) HTML 28K
22: R25 Equity (Tables) HTML 92K
59: R26 Net Loss per Share Attributable to Common HTML 62K
Stockholders (Tables)
63: R27 The Company and Basis of Presentation - Additional HTML 60K
Information (Detail)
28: R28 Medicis Settlement - Additional Information HTML 49K
(Detail)
27: R29 Cash Equivalents and Investments (Details) HTML 44K
30: R30 Fair Value Measurements - Schedule of Fair Value HTML 53K
of Financial Instruments (Detail)
31: R31 Fair Value Measurements - Summary of Changes in HTML 27K
Fair Value of Financial Instruments (Detail)
33: R32 Notes Payable and Financing Obligation - Hercules HTML 54K
Notes Payable (Detail)
21: R33 Notes Payable and Financing Obligation - Essex HTML 58K
Capital Notes (Detail)
57: R34 Notes Payable and Financing Obligation - Summary HTML 29K
of Aggregate Total Future Minimum Lease Payments
under the Financing Obligation (Detail)
38: R35 Convertible Notes, Warrants, and Related HTML 61K
Derivatives - Additional Information (Detail)
40: R36 Interest Expense - Summary of Interest Expense by HTML 42K
Cash and Non-Cash Components (Detail)
24: R37 Commitments and Contingencies - Additional HTML 34K
Information (Detail)
65: R38 Commitments and Contingencies - Schedule of Future HTML 38K
Minimum Lease Payments under Non-Cancelable
Operating Leases (Detail)
18: R39 Warrants - Additional Information (Detail) HTML 28K
34: R40 Equity - Additional Information (Detail) HTML 69K
60: R41 Equity - Fair Value Assumptions (Details) HTML 44K
23: R42 Equity - Schedule of Stock-based Compensation HTML 30K
Expense (Details)
26: R43 Equity - Schedule of Accumulated Other HTML 33K
Comprehensive Income (Details)
29: R44 Net Loss per Share Attributable to Common HTML 45K
Stockholders - Schedule of Computation of Basic
and Diluted Net Income (Loss) Per Share
Attributable to Common Stockholders (Detail)
36: R45 Net Loss per Share Attributable to Common HTML 34K
Stockholders - Summary of Common Stock Equivalents
Excluded from Computation of Diluted Net Income
(Loss) Per Share (Detail)
20: R46 Subsequent Events (Details) HTML 46K
64: XML IDEA XML File -- Filing Summary XML 106K
19: EXCEL IDEA Workbook of Financial Reports XLSX 58K
12: EX-101.INS XBRL Instance -- rvnc-20150930 XML 1.30M
14: EX-101.CAL XBRL Calculations -- rvnc-20150930_cal XML 173K
15: EX-101.DEF XBRL Definitions -- rvnc-20150930_def XML 354K
16: EX-101.LAB XBRL Labels -- rvnc-20150930_lab XML 1.10M
17: EX-101.PRE XBRL Presentations -- rvnc-20150930_pre XML 636K
13: EX-101.SCH XBRL Schema -- rvnc-20150930 XSD 123K
47: ZIP XBRL Zipped Folder -- 0001479290-15-000010-xbrl Zip 149K
| Exhibit |
1. | I have reviewed this Form 10-Q of Revance Therapeutics, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The
registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being prepared; |
(b) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(c) | Disclosed in this report any change in the
registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer(s) and I have disclosed, based
on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
(b) | Any
fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
/s/
L. Daniel Browne | |
President and Chief Executive Officer (Principal Executive Officer) | |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 11/10/15 | None on these Dates | ||
| For Period end: | 9/30/15 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/29/24 Revance Therapeutics, Inc. S-8 2/29/24 4:123K 2/28/24 Revance Therapeutics, Inc. 10-K 12/31/23 110:12M 2/28/23 Revance Therapeutics, Inc. S-8 2/28/23 5:192K 2/28/23 Revance Therapeutics, Inc. 10-K 12/31/22 109:14M 2/28/22 Revance Therapeutics, Inc. S-8 2/28/22 5:197K 2/28/22 Revance Therapeutics, Inc. 10-K 12/31/21 106:12M 2/25/21 Revance Therapeutics, Inc. 10-K 12/31/20 109:12M 1/29/21 Revance Therapeutics, Inc. S-8 1/29/21 3:137K |